Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Halobetasol Propionate and Tazarotene Topical Lotion Equivalence Study
NCT05282771Phase 1Completed
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Halobetasol propionate 0.05% lotion and tazarotene in plaque psoriasis (3 arms). Primary endpoint: Proportion of subjects with Treatment Success on the Investigator's Global Assessment (IGA) at 8 weeks. Started Apr 2021; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotiontazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05282771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282771.